Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint
CARMELINA®1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Trajenta® (linagliptin) demonstrating similar cardiovascular safety compared to placebo. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today positive top-line results, which evaluated the impact of treatment with linagliptin vs. placebo on cardiovascular safety on top of standard of care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005409/en/
The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.1 The majority of patients also had kidney disease, an important risk factor for cardiovascular disease. The overall safety profile of linagliptin in CARMELINA®, including adults with kidney disease, was consistent with previous data and no new safety signal was observed.
People who have diabetes are at an increased risk of cardiovascular disease and chronic kidney disease.2,3 Despite recent advancements in treatment options, cardiovascular disease remains the leading cause of death for people living with diabetes,4 and about two thirds of chronic kidney disease cases are attributable to metabolic conditions, such as diabetes, obesity and hypertension.5,6,7
“CARMELINA® reinforces the long-term clinical safety profile of linagliptin in adults with type 2 diabetes, even in those most vulnerable for vascular complications,” said Waheed Jamal, MD, Corporate Vice President and Head of Cardiometabolic Medicine, Boehringer Ingelheim. “The trial adds important new evidence for patients at high risk for heart and kidney disease, a population that has previously been underrepresented in other cardiovascular outcome trials in diabetes.”
“Linagliptin demonstrated cardiovascular safety in adults with type 2 diabetes and high vascular risk, with no need for dose adjustments regardless of kidney function,” added Jeff Emmick, MD, PhD, Vice President, Product Development, Lilly Diabetes. “CARMELINA® provides confidence in linagliptin as an effective and well-tolerated treatment, with a simple dosing regimen, for adults with type 2 diabetes.”
The full results of CARMELINA® will be presented on 4 October at the 54th European Association for the Study of Diabetes Annual Meeting in Berlin, Germany.
About the Study
CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) is a multi-national, randomised, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.1 The study was designed to assess the effect of Trajenta® (linagliptin) (5 mg once daily) compared to placebo (both added to standard of care) on cardiovascular outcome in adults with type 2 diabetes and cardiovascular risk, the majority of whom also had kidney disease. This population reflects patients that doctors see in their daily practice. CARMELINA® was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. Compared to other recently reported outcome trials of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes, CARMELINA® included the highest number of patients with impaired kidney function.*
Standard of care included both glucose lowering agents and cardiovascular drugs (including antihypertensive and lipid lowering agents).
Trajenta® is a one dose, once daily DPP-4-inihibitor that provides significant efficacy in the reduction of blood sugar levels for adults with type 2 diabetes. It can be prescribed for people with type 2 diabetes regardless of age, disease duration, ethnicity, body mass index (BMI), liver and kidney function.8 Trajenta® has the lowest kidney excretion rate of all DPP-4 inhibitors.8,9,10,11,12 It is prescribed at the same dose and has demonstrated proven efficacy regardless of kidney function,8,13,14 making it simple to administer and use.
About our cardiovascular outcome trials
Cardiovascular outcome trials are highly relevant, as cardiovascular disease is a major complication and the leading cause of death in type 2 diabetes. Worldwide, most people with type 2 diabetes die of a cardiovascular event.15 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME® with the SGLT2 inhibitor empagliflozin, which demonstrated a 38% relative risk reduction in cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.†16,17
CARMELINA® is one of two cardiovascular outcome trials with the DPP-4 inhibitor linagliptin. CAROLINA®,18 will be the first DPP-4 inhibitor cardiovascular outcome trial to compare commonly used second line treatments - linagliptin and the sulphonylurea glimepiride. This trial includes adults with type 2 diabetes at increased cardiovascular risk, however, the majority did not yet have heart and kidney disease. The study is expected to complete in 2018. CARMELINA® and CAROLINA® will provide the most comprehensive clinical database on the long-term safety profile of a DPP-4-inhibitor in a broad range of adults with type 2 diabetes.
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/CARMELINA-high-level
* glomerular filtration rate below 30 mL/min/m2
† Adult patients with type 2 diabetes and coronary artery disease, peripheral artery disease, or a history of myocardial infarction or stroke
Phone: +49 (6132) 77 2012
Manager, Global Business Communications
Phone: +1 (317) 954 9907
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Mouser Electronics and Grant Imahara Launch New Series All Things IoT about Technology Redefining How We Live17.10.2018 15:40 | Pressemelding
Mouser Electronics Inc. and celebrity engineer Grant Imahara today released a new video introducing All Things IoT, the latest series in Mouser’s award-winning Empowering Innovation Together™ program. The All Things IoT series is sponsored by Mouser’s valued suppliers Digi International, Maxim Integrated, Murata and TE Connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005655/en/ Global distributor Mouser Electronics and engineer spokesperson Grant Imahara team up to launch All Things IoT, the latest series in Mouser's Empowering Innovation Together program. The new series kicks off with Imahara's visit to the HPE IoT Innovation Lab in Houston to learn how the Internet of Things is impacting our workplaces and cities. To learn more, visit www.mouser.com/empowering-innovation/all-things-iot. (Photo: Business Wire) In the new video, Imahara and Mouser explore the complexities of life rooted in the Internet of T
Telefónica Deutschland Selects Mavenir vIMS for Deployment on ‘UNICA’17.10.2018 14:59 | Pressemelding
Mavenir, the leader in accelerating and redefining mobile network economics transformation for Communications Service Providers (CSPs), today announced that Telefónica Deutschland (FWB: O2D) is deploying Mavenir’s virtualized IMS solution (vIMS) for VoLTE and VoWiFi in their nationwide UNICA Data Centers Infrastructure, which is based on the Telefónica Group blueprint for Network Functions Virtualization (NFV) architecture. The solution will support mobile and fixed services for more than 45 million customer connections. The NFV environment is based on OpenStack® and will include automation, life cycle management and integration with Management and Orchestration (MANO) capabilities from the Telefónica UNICA platform. The Mavenir advanced vIMS solution will enable automation from day one and will support existing voice digital services as well as the launch of new services. As a software-based company leading the Telco NFV industry, Mavenir is a perfect match with Telefónica UNICA NFV s
Lenovo and Scale Computing Collaborate to Solve Edge Infrastructure Challenges for Retailers17.10.2018 14:34 | Pressemelding
Lenovo (HKSE: 992) (ADR: LNVGY), a Global Fortune 500 company and a technology leader in Intelligent Transformation, and Scale Computing, a market leader in intelligent edge solutions, today announced a global partnership and a new joint product providing a solution for edge infrastructure for global retailers, distributed enterprises and small and medium-sized businesses. The solution is ideal for highly distributed, on-premise environments, such as retail stores or bank branches, with multiple locations managed by the enterprise from a central location. Lenovo’s broad range of servers combined with efficient, intelligent edge infrastructure software from Scale Computing deliver a simple, self-healing, highly-available platform for running applications at the edge or hybrid edge-and-cloud. The Scale Computing HC3 Edge Platform on Lenovo Servers replaces traditional complex and expensive on-premise infrastructure with a modern solution optimized for environments where application uptim
As Hilton Nears 100-Year Milestone, New Research Uncovers a World-Changing Impact17.10.2018 13:24 | Pressemelding
As Hilton (NYSE: HLT) heads toward a milestone 100th anniversary in 2019, best-selling author and Stanford Business professor Chip Heath will unveil the impact the first global hotel company has had around the world in a new book titled The Hilton Effect. Business author Karla Starr joined him in the examination of the company founded by Conrad Hilton, a dreamer who aspired to create much more than just a comfortable place to sleep. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005486/en/ As Hilton nears 100-year milestone, new research uncovers a world-changing impact. (Graphic: Business Wire) Over the last century, Hilton has grown from a single hotel in Cisco, Texas, to nearly 5,500 hotels and 14 brands in 106 countries and territories. Hilton’s hotels have hosted more than 3 billion guests since 1919 and enlisted nearly 10 million Team Members in the company’s mission to fill the Earth with the light and warmth of
Infovista Announces Channel Go-to-Market Strategy for 5G, Application-Aware SD-WAN Solutions17.10.2018 13:00 | Pressemelding
Reinforcing its commitment to the channel to deliver its industry-leading 5G, application-aware SD-WAN and network testing solutions to market, Infovista, the leader in modern network performance, today announced its go-to-market strategy is “all indirect, all the time.” To accelerate its global channel strategy, Infovista has hired industry veteran Jon Howes as senior vice president, global channel sales. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005042/en/ Jon Howes, Senior Vice President Global Channel Sales (Photo: Business Wire) Howes is responsible for leading Infovista’s indirect go-to-market strategy for all products. Howes, an accomplished channel leader with a long history of managing high-performance channel and business development teams, has expertise spanning multiple geographies in both service provider and enterprise end user environments. Prior to joining Infovista, Howes built channels for Junipe
Smart Link Accelerates Digital Service Expansion with Avaya Cloud Contact Center Solutions17.10.2018 12:37 | Pressemelding
Smart Link, a subsidiary of Al Khaleej for Training and Education and a leading Saudi-based Business Process Outsourcing (BPO) company, has teamed up with Avaya Holdings Corp. (NYSE:AVYA) to accelerate Smart Link’s expansion and the diversification of its digital services portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005478/en/ Avaya signs a Memorandum of Understanding with Smart Link during GITEX Technology Week 2018 (Photo: Business Wire) The two companies signed a Memorandum of Understanding (MoU) during GITEX Technology Week with a focus on digital and cloud-based solutions that will enable Smart Link to have greater agility and flexibility in meeting its customers’ demands for digital services. In alignment with Saudi Vision 2030, Smart Link is digitalizing and automating all possible duties to increase its human value while delivering cutting-edge communication solutions to connect government and priv